Currently Viewing:
American Heart Association Scientific Sessions 2019
Kiersten Combs Discusses Findings of the DAPA-HF Study in Population Without Diabetes
November 17, 2019
Dr Jay Edelberg Outlines the Clinical Burdens and Treatment Options for Hypertrophic Cardiomyopathy
November 17, 2019
Details of DAPA-HF Results Point to Dapagliflozin for Some Heart Failure Patients Without Diabetes
November 17, 2019
In Stable Heart Disease, Study Finds Stents Might Be No Better Than Drugs
November 17, 2019
Dapagliflozin Meets Quality-of-Life Marks, Efficacy Among Seniors, Data Show
November 17, 2019
From Self-Reporting Accuracy to Therapy Access: AHA Posters Cover Issues in Disparities
November 18, 2019
Dr John Pfeifer Outlines Necessary Steps for Preventive Action in Patients With Atrial Fibrillation
November 18, 2019
Sara Levintow Analyzes 2013 ACC/AHA Cholesterol Guidelines in Relation to Trends in US Lipid Testing
November 18, 2019
Plaques May Be Key to Vascepa's Role in Preventing CV Events
November 18, 2019
48-Week Results for Mavacamten Draw Crowd at AHA Session
November 19, 2019
Dr Vinay Kini Discusses the Growing Influence of the EHR in the Transition to Value-Based Care
November 19, 2019
Dr Stephen Heitner Details the Significance of the PIONEER-OLE Study in Treating Obstructive HCM
November 19, 2019
Dr Stephen Heitner Outlines the Next Steps After MAVERICK-HCM Study Findings
November 21, 2019
Dr Stephen Voyce Details Innovations and Preventive Strategies in Detection of Atrial Fibrillation
November 24, 2019
Dr Brent Williams Discusses Study Findings on Detection of Atrial Fibrillation
November 27, 2019
Dr Brandon Fornwalt Discusses the Preventive Efficacy of AI in Monitoring for Atrial Fibrillation
November 30, 2019
Dr Douglas Losordo Discusses the Evolution and Importance of CD34+ Treatment in Patients With CMD
December 04, 2019
Dr Brian Ghoshhajra Details the Significance of the PDS-2 System in Affecting Progression of HoFH
December 05, 2019
Dr Roland Chen Outlines the GUARD-AF Trial as a Preventive Mechanism in Reducing Risk of Stroke
December 06, 2019
Dr Darryl Sleep: Identifying and Treating Elevated LDL-C in Patients Can Mitigate Heart Attack Risk
December 06, 2019
Dr C. Noel Bairey Merz Discusses ESCaPE-CMD Phase 2 Study Results of Patients With CMD
January 03, 2020
Dr Javed Butler Discusses Why People With Diabetes Are at Greater Risk of Heart Failure
January 11, 2020
Dr Jay Edelberg Discusses PIONEER-OLE and Design of EXPLORER-HCM in Patients With Obstructive HCM
January 16, 2020
Dr Jay Edelberg Explains Preventive Efficacy and Potential FDA Approval of Mavacamten
January 26, 2020
Currently Reading
Dr Roland Chen Discusses the Primary Endpoints of the GUARD-AF Trial for Atrial Fibrillation
January 31, 2020

Dr Roland Chen Discusses the Primary Endpoints of the GUARD-AF Trial for Atrial Fibrillation

The GUARD-AF trial will allow us to look at both the benefits and the risks of screening for atrial fibrillation and the reduction of stroke, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.


The GUARD-AF trial will allow us to look at both the benefits and the risks of screening for atrial fibrillation and the reduction of stroke, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.

Transcript

What are some of the primary endpoints being sought by the GUARD-AF trial? How are healthcare claims being utilized to distinguish evidence on health outcomes associated with atrial fibrillation?

The primary efficacy endpoint in GUARD-AF is actually stroke that leads to a hospital evaluation. The primary safety endpoint in GUARD-AF is bleeding that leads to hospitalization. So, GUARD-AF will actually allow us to look at both the benefits and the risks of screening for atrial fibrillation and the reduction of stroke. Healthcare claims are important in this study, because healthcare claims will actually be used to identify the occurrence of these primary endpoints because these patients are receiving Medicare as their health insurance. So this study, although it's a clinical study where patients are randomized, is actually being conducted in a real world setting. So, healthcare claims will be an important part of this pragmatic trial.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up